Natixis Advisors LLC Sells 17,779 Shares of Labcorp Holdings Inc. $LH

Posted by on Jun 3rd, 2026

Natixis Advisors LLC decreased its position in shares of Labcorp Holdings Inc. (NYSE:LH – Free Report) by 4.7% in the 4th quarter, HoldingsChannel reports. The firm owned 364,387 shares of the medical research company’s stock after selling 17,779 shares during the quarter. Natixis Advisors LLC’s holdings in Labcorp were worth $91,417,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of LH. Norges Bank bought a new stake in Labcorp during the fourth quarter worth about $248,006,000. Victory Capital Management Inc. lifted its position in Labcorp by 20.0% during the third quarter. Victory Capital Management Inc. now owns 2,637,350 shares of the medical research company’s stock worth $756,878,000 after purchasing an additional 440,224 shares during the period. Wellington Management Group LLP lifted its position in Labcorp by 15.9% during the third quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company’s stock worth $604,488,000 after purchasing an additional 289,029 shares during the period. Marshall Wace LLP lifted its position in Labcorp by 79.1% during the third quarter. Marshall Wace LLP now owns 623,550 shares of the medical research company’s stock worth $178,996,000 after purchasing an additional 275,454 shares during the period. Finally, Mondrian Investment Partners LTD bought a new stake in Labcorp during the third quarter worth about $75,208,000. Institutional investors own 95.94% of the company’s stock.

Insider Activity

In other news, CEO Adam H. Schechter sold 5,903 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $254.50, for a total value of $1,502,313.50. Following the completion of the transaction, the chief executive officer owned 107,234 shares of the company’s stock, valued at $27,291,053. This represents a 5.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.84% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

LH has been the subject of several research analyst reports. Piper Sandler boosted their target price on Labcorp from $270.00 to $300.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 24th. Morgan Stanley reissued an “overweight” rating on shares of Labcorp in a research note on Tuesday, February 17th. Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Weiss Ratings reissued a “buy (b-)” rating on shares of Labcorp in a research note on Friday, May 8th. Finally, Evercore reissued an “outperform” rating and set a $300.00 target price on shares of Labcorp in a research note on Wednesday, April 8th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $308.00.

Get Our Latest Report on LH

Labcorp Stock Performance

Labcorp stock opened at $257.27 on Wednesday. The business has a 50 day moving average of $263.08 and a 200-day moving average of $265.78. Labcorp Holdings Inc. has a 1 year low of $241.81 and a 1 year high of $293.72. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.73 and a quick ratio of 1.54. The company has a market capitalization of $21.10 billion, a P/E ratio of 22.79, a P/E/G ratio of 1.80 and a beta of 0.90.

Labcorp (NYSE:LH – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.09 by $0.16. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The company had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.51 billion. During the same quarter in the prior year, the firm posted $3.84 earnings per share. The firm’s revenue was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, equities research analysts predict that Labcorp Holdings Inc. will post 17.99 earnings per share for the current year.

Labcorp Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Stockholders of record on Friday, May 29th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Friday, May 29th. This represents a $2.88 annualized dividend and a dividend yield of 1.1%. Labcorp’s dividend payout ratio is currently 25.51%.

About Labcorp

(Free Report)

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.

Featured Stories

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Labcorp Holdings Inc. (NYSE:LH – Free Report).

Institutional Ownership by Quarter for Labcorp (NYSE:LH)

Receive News & Ratings for Labcorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Labcorp and related companies with MarketBeat.com's FREE daily email newsletter.